Generated by DeepSeek V3.2| Tim Hunt | |
|---|---|
| Name | Tim Hunt |
| Caption | Hunt in 2001 |
| Birth date | 19 February 1943 |
| Birth place | Neston, Cheshire, England |
| Nationality | British |
| Fields | Biochemistry, Cell biology |
| Workplaces | University of Cambridge, ICRF (Cancer Research UK), Marine Biological Laboratory |
| Alma mater | University of Cambridge (Clare College) |
| Doctoral advisor | Asher Korner |
| Known for | Discovery of cyclin, Cell cycle regulation |
| Prizes | Nobel Prize in Physiology or Medicine (2001), Royal Medal (2006), Sir Hans Krebs Medal |
| Spouse | Mary Collins |
Tim Hunt. Sir Richard Timothy Hunt is a British biochemist and molecular physiologist who was awarded the Nobel Prize in Physiology or Medicine in 2001. He shares the prize with Leland H. Hartwell and Paul Nurse for their discoveries of key regulators of the cell cycle. Hunt is best known for his identification of cyclin, a protein that oscillates in concentration during cell division, a fundamental breakthrough in understanding cellular reproduction and its implications for diseases like cancer.
Born in Neston, Cheshire, he was the son of Richard William Hunt, a Keeper of Western Manuscripts at the Bodleian Library in Oxford. He developed an early interest in science, particularly chemistry, while attending Magdalen College School, Oxford. Hunt proceeded to study Natural Sciences at the University of Cambridge, specifically at Clare College. His undergraduate studies culminated in 1964, after which he began his doctoral research in the Department of Biochemistry at Cambridge under the supervision of Asher Korner, investigating protein synthesis in reticulocytes.
After completing his PhD in 1968, Hunt conducted postdoctoral work at the Albert Einstein College of Medicine in New York City. He returned to England in 1971 to join the Laboratory of Molecular Biology in Cambridge. In 1982, he moved to the Imperial Cancer Research Fund (ICRF, later part of Cancer Research UK) laboratories in South Mimms. It was during summer experiments at the Marine Biological Laboratory in Woods Hole, Massachusetts in the early 1980s, using eggs from the Atlantic surf clam, that he made his seminal discovery. He observed that a specific protein was synthesized and then degraded in phase with each cell division cycle, which he named cyclin. This work, published in the journal *Nature*, revolutionized understanding of cell cycle control and established cyclins as crucial activators of cyclin-dependent kinases.
In 2001, the Nobel Assembly at the Karolinska Institute awarded the Nobel Prize in Physiology or Medicine jointly to Hunt, Leland H. Hartwell, and Paul Nurse. The prize recognized their complementary work in elucidating the universal mechanism that controls the eukaryotic cell cycle. Hunt's specific contribution, the discovery of cyclins, provided the essential link between periodic protein synthesis and the engine of cell division. The award ceremony in Stockholm highlighted the profound impact of this basic research on oncology and developmental biology.
In June 2015, while speaking at the World Conference of Science Journalists in Seoul, Hunt made controversial remarks about the "trouble with girls" in laboratories. His comments, which he later stated were intended as a light-hearted, self-critical anecdote, sparked immediate international condemnation and accusations of sexism in science. Facing intense media scrutiny and criticism from institutions like University College London and the Royal Society, he resigned from his honorary professorship at UCL and his position on the Royal Society's Biological Sciences Awards Committee. The incident ignited a widespread debate about gender equality in STEM fields and the culture of academic science.
Following the controversy, Hunt continued his scientific work, maintaining an association with the Marine Biological Laboratory and serving as a scientist emeritus at the Francis Crick Institute. His legacy remains firmly rooted in his transformative cell cycle research. The cyclin pathway is a primary target in cancer therapy, with drugs like palbociclib designed to inhibit CDK4/6. He has been recognized with numerous honors including a knighthood in 2006, the Royal Medal, and the Sir Hans Krebs Medal. Despite the personal turmoil of 2015, his foundational contributions to molecular biology continue to influence both basic research and clinical medicine globally.
Category:British biochemists Category:Nobel laureates in Physiology or Medicine Category:1943 births Category:Recipients of the Royal Medal Category:Fellows of the Royal Society